Dr. Schecter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
920 US-202 S
Raritan, NJ 08869Phone+1 908-927-3159- Is this information wrong?
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2007
- Brown UniversityInternship, Internal Medicine, 2004 - 2005
- The Warren Alpert Medical School of Brown UniversityClass of 2004
Certifications & Licensure
- NY State Medical License 2006 - 2025
Clinical Trials
- Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- 180 citationsCiltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen
Journal of Clinical Oncology. 2023-02-20 - 16 citationsAugmentation with open-label atomoxetine for partial or nonresponse to antidepressants.Linda L. Carpenter, Nada Milosavljevic, Jordan M. Schecter, Audrey R. Tyrka, Lawrence H. Price
The Journal of Clinical Psychiatry. 2005-10-14 - 148 citationsDaratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised,...Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac
The Lancet. Oncology. 2021-06-01
Abstracts/Posters
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple MyelomaDecember 2021
Press Mentions
- DARZALEX® (Daratumumab)-Based Regimens Significantly Improve Clinical Outcomes in Both Transplant-Eligible and -Ineligible Patients Who Are Newly Diagnosed with Multiple MyelomaJune 6th, 2024
- FDA Panel Approves 2 New CAR-T TherapiesMarch 16th, 2024
- Treatment with CARVYKTI®▼ (Ciltacabtagene Autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple MyelomaDecember 16th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: